TY - JOUR
T1 - Association of Kidney Function Measures With Signs of Neurodegeneration and Small Vessel Disease on Brain Magnetic Resonance Imaging
T2 - The Atherosclerosis Risk in Communities (ARIC) Study
AU - Scheppach, Johannes B.
AU - Wu, Aozhou
AU - Gottesman, Rebecca F.
AU - Mosley, Thomas H.
AU - Arsiwala-Scheppach, Lubaina T.
AU - Knopman, David S.
AU - Grams, Morgan E.
AU - Sharrett, A. Richey
AU - Coresh, Josef
AU - Koton, Silvia
N1 - Funding Information:
Johannes B. Scheppach, MD, Aozhou Wu, PhD, Rebecca F. Gottesman, MD, PhD, Thomas H. Mosley, PhD, Lubaina T. Arsiwala-Scheppach, MHS, David S. Knopman, MD, Morgan E. Grams, PhD, A. Richey Sharrett, DrPH, Josef Coresh, PhD, and Silvia Koton, PhD. Research concept and study design: JBS, AW, ARS, JC, SK; acquisition, analysis, or interpretation of data: all authors; statistical analysis: JBS; supervision or mentorship: ARS, JC, SK. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated, and resolved, including with documentation in the literature if appropriate. This article was prepared while Dr. Rebecca Gottesman was employed at the Johns Hopkins University. The opinions expressed in this article are the author's own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States Government. The ARIC Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). Neurocognitive data were collected with support by grants U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, and 2U01HL096917 from the National Institutes of Health (National Heart, Lung, and Blood Institute, with support from the National Institute of Neurological Disorders and Stroke, National Institute on Aging, and National Institute on Deafness and Other Communication Disorders) and with previous brain MRI examinations funded by R01-HL70825 from the National Heart, Lung, and Blood Institute. Dr Grams is supported by K24HL155861 and R01DK124399. Dr Scheppach was funded by a research fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft, Projekt SCHE 2116/1-1). The funding sources had no role in the study design and conduct of the study, collection, management, analysis, reporting, and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication. Dr Scheppach has received a research fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft, Projekt SCHE 2116/1-1). Dr Wu has received consulting fees from Analysis Group Inc, which was not relevant to the presented study. Dr Gottesman has previously received funding (through her institution) from NIH/NHLBI, NIH/NIA, and NIH/NINDS for ARIC grant support, and has previously served as associate editor for the journal Neurology. Dr Mosley has received support from NIH grants. Dr Grams has received support from NKF and NIH grants. Dr Coresh has received support from NKF and NIH grants and has served as an advisor to Healthy.io. The remaining authors declare that they have no relevant financial interests. We thank the staff and participants of the ARIC Study for their important contributions. Received March 10, 2022. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and a Deputy Editor who served as Acting Editor-in-Chief. Accepted in revised form July 21, 2022. The involvement of an Acting Editor-in-Chief was to comply with AJKD's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.
Funding Information:
Dr Scheppach has received a research fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft, Projekt SCHE 2116/1-1). Dr Wu has received consulting fees from Analysis Group Inc, which was not relevant to the presented study. Dr Gottesman has previously received funding (through her institution) from NIH/NHLBI, NIH/NIA, and NIH/NINDS for ARIC grant support, and has previously served as associate editor for the journal Neurology. Dr Mosley has received support from NIH grants. Dr Grams has received support from NKF and NIH grants. Dr Coresh has received support from NKF and NIH grants and has served as an advisor to Healthy.io. The remaining authors declare that they have no relevant financial interests.
Funding Information:
The ARIC Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). Neurocognitive data were collected with support by grants U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, and 2U01HL096917 from the National Institutes of Health ( National Heart, Lung, and Blood Institute , with support from the National Institute of Neurological Disorders and Stroke , National Institute on Aging , and National Institute on Deafness and Other Communication Disorders ) and with previous brain MRI examinations funded by R01-HL70825 from the National Heart, Lung, and Blood Institute . Dr Grams is supported by K24HL155861 and R01DK124399. Dr Scheppach was funded by a research fellowship from the German Research Foundation ( Deutsche Forschungsgemeinschaft , Projekt SCHE 2116/1-1). The funding sources had no role in the study design and conduct of the study, collection, management, analysis, reporting, and interpretation of the data, preparation, review, or approval of the manuscript, and decision to submit the manuscript for publication.
Publisher Copyright:
© 2022 National Kidney Foundation, Inc.
PY - 2023/3
Y1 - 2023/3
N2 - Rationale & Objective: Chronic kidney disease (CKD) is a risk factor for cognitive decline, but evidence is limited on its etiology and morphological manifestation in the brain. We evaluated the association of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) with structural brain abnormalities visible on magnetic resonance imaging (MRI). We also assessed whether this association was altered when different filtration markers were used to estimate GFR. Study Design: Cross-sectional study nested in a cohort study. Setting & Participants: 1,527 participants in the Atherosclerosis Risk in Communities (ARIC) Study. Predictors: Log(UACR) and eGFR based on cystatin C, creatinine, cystatin C and creatinine in combination, or β2-microglobulin (B2M). Outcomes: Brain volume reduction, infarcts, microhemorrhages, white matter lesions. Analytical Approach: Multivariable linear and logistic regression models fit separately for each predictor based on a 1-IQR difference in the predictor value. Results: Each 1-IQR lower eGFR was associated with reduced cortex volume (regression coefficient: −0.07 [95% CI, −0.12 to −0.02]), greater white matter hyperintensity volume (logarithmically transformed; regression coefficient: 0.07 [95% CI, 0.01-0.15]), and lower white matter fractional anisotropy (regression coefficient: −0.08 [95% CI, −0.17 to −0.01]). The results were similar when eGFR was estimated with different equations based on cystatin C, creatinine, a combination of cystatin C and creatinine, or B2M. Higher log(UACR) was similarly associated with these outcomes as well as brain infarcts and microhemorrhages (odds ratios per 1-IQR-fold greater UACR of 1.31 [95% CI, 1.13-1.52] and 1.30 [95% CI, 1.12-1.51], respectively). The degree to which brain volume was lower in regions usually susceptible to Alzheimer disease and LATE (limbic-predominant age-related TDP-43 [Tar DNA binding protein 43] encephalopathy) was similar to that seen in the rest of the cortex. Limitations: No inference about longitudinal effects due to cross-sectional design. Conclusions: We found eGFR and UACR are associated with structural brain damage across different domains of etiology, and eGFR- and UACR-related brain atrophy is not selective for regions typically affected by Alzheimer disease and LATE. Hence, Alzheimer disease or LATE may not be leading contributors to neurodegeneration associated with CKD.
AB - Rationale & Objective: Chronic kidney disease (CKD) is a risk factor for cognitive decline, but evidence is limited on its etiology and morphological manifestation in the brain. We evaluated the association of estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR) with structural brain abnormalities visible on magnetic resonance imaging (MRI). We also assessed whether this association was altered when different filtration markers were used to estimate GFR. Study Design: Cross-sectional study nested in a cohort study. Setting & Participants: 1,527 participants in the Atherosclerosis Risk in Communities (ARIC) Study. Predictors: Log(UACR) and eGFR based on cystatin C, creatinine, cystatin C and creatinine in combination, or β2-microglobulin (B2M). Outcomes: Brain volume reduction, infarcts, microhemorrhages, white matter lesions. Analytical Approach: Multivariable linear and logistic regression models fit separately for each predictor based on a 1-IQR difference in the predictor value. Results: Each 1-IQR lower eGFR was associated with reduced cortex volume (regression coefficient: −0.07 [95% CI, −0.12 to −0.02]), greater white matter hyperintensity volume (logarithmically transformed; regression coefficient: 0.07 [95% CI, 0.01-0.15]), and lower white matter fractional anisotropy (regression coefficient: −0.08 [95% CI, −0.17 to −0.01]). The results were similar when eGFR was estimated with different equations based on cystatin C, creatinine, a combination of cystatin C and creatinine, or B2M. Higher log(UACR) was similarly associated with these outcomes as well as brain infarcts and microhemorrhages (odds ratios per 1-IQR-fold greater UACR of 1.31 [95% CI, 1.13-1.52] and 1.30 [95% CI, 1.12-1.51], respectively). The degree to which brain volume was lower in regions usually susceptible to Alzheimer disease and LATE (limbic-predominant age-related TDP-43 [Tar DNA binding protein 43] encephalopathy) was similar to that seen in the rest of the cortex. Limitations: No inference about longitudinal effects due to cross-sectional design. Conclusions: We found eGFR and UACR are associated with structural brain damage across different domains of etiology, and eGFR- and UACR-related brain atrophy is not selective for regions typically affected by Alzheimer disease and LATE. Hence, Alzheimer disease or LATE may not be leading contributors to neurodegeneration associated with CKD.
KW - Albuminuria
KW - Atherosclerosis Risk in Communities (ARIC) Study
KW - brain infarcts
KW - cerebral small vessel disease
KW - chronic kidney disease (CKD)
KW - creatinine
KW - cystatin C
KW - diffusion tensor imaging
KW - estimated glomerular filtration rate (eGFR)
KW - magnetic resonance imaging (MRI)
KW - microhemorrhages
KW - neurodegeneration
KW - urinary albumin-creatinine ratio (UACR)
KW - white matter lesions
KW - β-microglobulin (B2M)
UR - http://www.scopus.com/inward/record.url?scp=85142691001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142691001&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2022.07.013
DO - 10.1053/j.ajkd.2022.07.013
M3 - Article
C2 - 36179945
AN - SCOPUS:85142691001
SN - 0272-6386
VL - 81
SP - 261-269.e1
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 3
ER -